Completed PHASE1 INTERVENTIONAL 1-arm NCT00993239

Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

Sponsor: TetraLogic Pharmaceuticals

Conditions Cancer

Interventions Birinapant (TL32711)

Updated 6 times since 2017 Last updated: Mar 1, 2016 Started: Nov 30, 2009 Primary completion: Aug 31, 2012 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00993239, this PHASE1 trial focuses on Cancer and remains completed. Sponsored by TetraLogic Pharmaceuticals, it has been updated 6 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

TetraLogic Pharmaceuticals

Data source: TetraLogic Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States
• Philadelphia, United States